Renal denervation consensus paper now published in hypertension research journal
June 3, 2022
The paper contains guidelines developed by local medical experts and will also be made
available to the public.
The consensus paper on renal denervation developed by the Malaysian Renal Nerve Denervation Working Group (MyRDN), a collaboration between the Malaysian Society of Hypertension and the National Heart Association of Malaysia, has been accepted for publication into the specialised Hypertension Research medical journal. The paper, which provides recommendations and guidelines for healthcare professionals on the use of renal denervation in the treatment of people with hypertension, was peer-reviewed by industry professionals and has been published in the journal for healthcare professionals and is now accessible to the public.
Dr Alan Fong, President of the National Heart Association of Malaysia (NHAM), said: “We are proud that our consensus paper, which was wholly produced by Malaysian specialists, has been published by the Hypertension Research Journal, which is the official journal of the Japanese Society of Hypertension. This journal publishes high quality original research specifically in the area of hypertension, or high blood pressure, and other related heart diseases.” The consensus paper will also be available as an open access document on the Hypertension Research Journal website for healthcare professionals and the public to refer. Professor Datin Dr Chia Yook Chin, Co-Chair of MyRDN, said: “It is important that both the healthcare professionals and members of the public have access to these recommendations and guidelines for the use of renal denervation. The doctors and patients can discuss the suitability of this procedure on an individual basis and come to a decision together. This is particularly important as the consensus paper states that patient preference is one of the considerations in the decision to proceed with this procedure.” Renal denervation is a minimally-invasive procedure where radiofrequency waves are targeted at the renal (kidney) sympathetic nerves in order to reduce their activities, which contributes to hypertension. Among the types of patients recommended to undergo this procedure are those with resistant hypertension; those whose blood pressure still remains high despite being on the best combination of anti-hypertensive medications; those who consistently don’t take their medications regularly despite counseling, and those unwilling to be on long-term medication. 200,000 suffer from hypertension Fong noted that a study done in Sarawak found that around one in four patients involved in the research who were suspected of having resistant hypertension, did indeed have resistant hypertension. From there, the researchers (of whom Dr Fong was one) estimated that around 200,000 Malaysian adults had true resistant hypertension in 2021, based on national data. The study, which has been submitted to the NHAM Congress 2022, was conducted with the aim of filling in the gap in data surrounding the prevalence and epidemiology of true resistant hypertension in Malaysia. “It is important to have more accurate numbers related to resistant hypertension in Malaysia as patients with this form of hypertension face an even higher risk of heart and kidney disease than those with regular hypertension. Patients with resistant hypertension have the option of undergoing renal denervation as an adjunct treatment to help them lower their blood pressure, and thus, also decrease their risk of serious heart and kidney issues,” said Dr Fong. According to data from the first 80 patients involved in the ongoing SPYRAL HTN-ON MED clinical trial, those with uncontrolled hypertension despite being on anti-hypertensive medications, experienced an 18.7 mmHg decrease in systolic blood pressure as measured continuously over 24 hours via ambulatory monitoring, and a 20.9 mmHg decrease when measured in the office, three years after undergoing the procedure. In comparison, patients who underwent a sham procedure (i.e. a renal angiogram, rather than renal denervation) experienced an 8.6 mmHg decrease in systolic blood pressure as measured continuously over 24 hours via ambulatory monitoring, and a 12.5 mmHg decrease when measured in the office. The trial also demonstrated that the use of the Symplicity Spyral renal denervation catheter, to be safe in the long run, with no major device or procedural adverse events occurring throughout the three years under analysis. |
EXPLORE FURTHER
|
Diabetes: The top cause of chronic kidney disease1 in 3 adults with diabetes suffer from chronic kidney disease (CKD) and it affects up to 40% of patients with Type 2 diabetes.
|
|
Early warning signs of kidney cancerTumors often discovered incidentally; symptoms include painless haematuria and swelling
|
|
Pros and cons of getting a kidney transplantOnly half of dialysis patients survive five years post-treatment
|
|
Nephrologist says only 30 get into kidney donation programme from 21,000 in waiting listThe average waiting time for an organ transplant is between 14 and 16 years
|
|
National Kidney Foundation refutes claims of viral posting promoting a cure for kidney diseaseJisheng Kidney Qi tablets - a cure for kidney disease a scam, says NKF
|
|
Cranberries, high doses of vitamin C causes kidney stones, says clinical journalOxalate in cranberries a contributing factor
|
|
Mybuahpinggang.com website launched to empower kidney failure patients, caregivers nationwidePractical resources on kidney diseases, treatment, dialysis and transplant
|
|
National Kidney Foundation launches Red Bean assistance programme to aid patients with anemiaEnhancing CKD care with effective erythropoietin-stimulating agent (ESA) treatment for patients
|
